The use of pleural fluid sCD44v6/std ratio for distinguishing mesothelioma from other pleural malignancies

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 190-194

  Porcel, José M ^a   Esquerda, Aureli ^a   Rodriguez Panadero, Francisco ^b   Martínez Iribarren, Alicia ^a   Bielsa, Silvia ^a  

^a HOSPITAL ARNAU DE VILANOVA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Adenocarcinoma.; CD44; Mesothelioma; Pleural effusion

Indexed keywords

CD44V ANTIGEN; CD44V6 ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLEURA CANCER; PLEURA FLUID; PLEURA MESOTHELIOMA; PLEURA METASTASIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

EID: 78651107602     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318200f447     Document Type: Article

References (14)

1. Fassina A, Fedeli U, Corradin M, et al. Accuracy and reproducibility of pleural effusion cytology. Leg Med (Tokyo) 2008;10:20-25.
2. Husain AN, Colby TV, Ordoñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 2009; 133:1317-1331.
3. Ray M, Kindler HL. Malignant pleural mesothelioma. An update on biomarkers and treatment. Chest 2009;133:888-896.
4. Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 2009;180:437-444.
5. Naor D, Wallach-Dayan SN, Zahalka MA, et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-267.
6. Heider KH, Kuthan H, Stehle G, et al. CD44v6: a target for antibodybased cancer therapy. Cancer Immunol Immunother 2004;53:567-579.
7. Okamoto I, Morisaki T, Sasaki J, et al. Molecular detection of cancer cells by competitive reverse transcription-polymerase chain reaction analysis of specific CD44 variant RNAs. J Natl Cancer Inst 1998;90:307-315.
8. Tojo N, Inase N, Ichioka M, et al. Differential expression of CD44 splice variants in malignant and benign pleural effusions. Tohoku J Exp Med 1996;179:273-279.
9. Berner HS, Davidson B, Berner A, et al. Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions. Virchows Arch 2000;436:330-335.
10. Afify A, Pang L, Howell L. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids. Appl Immunohistochem Mol Morphol 2007;15:446-450.
11. Afify A, Lynne LC, Howell L. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions. Diagn Cytopathol 2007;35:105-110.
12. Attanoos RL, Webb R, Gibbs AR. CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma. Histopathology 1997;30:260-263.
13. Cury PM, Butcher DN, Fisher C, et al. Value of the mesotheliumassociated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mol Pathol 2000;13:107-112.
14. Afify AM, Stern R, Michael CW. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol 2005;32:145-150.